Get the Stockscreener App
21.42
5.85%
-1.33
Castle Biosciences Inc stock is traded at $21.42, with a volume of 301.73K.
It is down -5.85% in the last 24 hours and up +10.75% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$22.75
Open:
$22.75
24h Volume:
301.73K
Relative Volume:
0.60
Market Cap:
$621.36M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-9.9628
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-9.08%
1M Performance:
+10.75%
6M Performance:
+9.12%
1Y Performance:
-30.18%
1-Day Range:
$21.37
$22.88
1-Week Range:
$21.37
$24.74
52-Week Range:
$14.59
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.42 | 665.45M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Parkman Healthcare Partners LLC Has $7.02 Million Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Reports Strong Q2 2025 Financial Results - MSN
556,485 Shares in Castle Biosciences, Inc. $CSTL Purchased by Park West Asset Management LLC - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Receives "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cubist Systematic Strategies LLC Grows Stock Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Shows Improved Relative Price Performance; Still Shy Of Benchmark - MSN
New Data at American Foregut Society's 2025 Annual Meeting - GlobeNewswire
Castle Biosciences to Present New Findings on TissueCypher Barrett’s Esophagus Test at AFS 2025 Annual Meeting - Quiver Quantitative
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions - GlobeNewswire Inc.
Is Castle Biosciences Inc. benefiting from interest rate changesPrice Action & Fast Entry High Yield Stock Tips - beatles.ru
Castle Biosciences, Inc. $CSTL Shares Bought by Graham Capital Management L.P. - MarketBeat
Is Castle Biosciences Inc. undervalued by DCF analysisMarket Volume Summary & Risk Controlled Daily Trade Plans - 뉴스영
What does recent volatility data suggest for Castle Biosciences Inc.2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - Newser
What technical models suggest about Castle Biosciences Inc.’s comeback - Newser
What is the target price for Castle Biosciences Inc. stockQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - خودرو بانک
Candlestick signals on Castle Biosciences Inc. stock todayJuly 2025 Momentum & Daily Profit Focused Screening - Newser
Braidwell LP Buys New Stake in Castle Biosciences, Inc. $CSTL - MarketBeat
Can Castle Biosciences Inc. outperform in the next rallyQuarterly Performance Summary & Free High Return Stock Watch Alerts - خودرو بانک
Is Castle Biosciences Inc. forming bullish engulfing patternsPortfolio Return Summary & Weekly Return Optimization Alerts - خودرو بانک
Should you hold or exit Castle Biosciences Inc. nowJuly 2025 Movers & Real-Time Volume Analysis - Newser
Will earnings trigger a reversal in Castle Biosciences Inc.2025 Volume Leaders & Real-Time Volume Analysis - Newser
Sector ETF performance correlation with Castle Biosciences Inc.Weekly Trend Recap & Low Risk Profit Maximizing Plans - Newser
Is Castle Biosciences Inc. in a bullish channelJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - خودرو بانک
What moving averages say about Castle Biosciences Inc.2025 Price Targets & Smart Allocation Stock Reports - Newser
Russell Investments Group Ltd. Grows Stake in Castle Biosciences, Inc. $CSTL - MarketBeat
Is Castle Biosciences Inc. gaining market shareEarnings Performance Report & High Win Rate Trade Tips - خودرو بانک
Does Castle Biosciences Inc. have a sustainable dividendMarket Sentiment Report & Verified Technical Signals - خودرو بانک
Ranking Castle Biosciences Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Momentum Stock Entry Tips - Newser
Will Castle Biosciences Inc. see short term momentumPortfolio Growth Summary & Risk Managed Investment Signals - Newser
Is Castle Biosciences Inc. on track to beat earningsEarnings Recap Summary & Verified Entry Point Signals - خودرو بانک
Is Castle Biosciences Inc.’s ROE strong enoughJuly 2025 Trade Ideas & Precise Buy Zone Tips - خودرو بانک
Castle Biosciences (NASDAQ:CSTL) Rating Increased to Hold at Zacks Research - MarketBeat
How to forecast Castle Biosciences Inc. trends using time seriesPortfolio Update Report & Long-Term Safe Investment Plans - Newser
Should you wait for a breakout in Castle Biosciences Inc.Trade Volume Summary & Precise Buy Zone Identification - Newser
Castle Biosciences Inc. stock prediction for this weekMarket Sentiment Review & Weekly Hot Stock Watchlists - Newser
Using Ichimoku Cloud for Castle Biosciences Inc. technicalsPortfolio Profit Report & High Win Rate Trade Alerts - Newser
What is the PEG ratio of Castle Biosciences Inc.2025 Growth vs Value & Weekly High Conviction Ideas - خودرو بانک
News impact scoring models applied to Castle Biosciences Inc.Global Markets & Smart Swing Trading Alerts - Newser
Using economic indicators to assess Castle Biosciences Inc. potential2025 Fundamental Recap & Weekly Momentum Stock Picks - Newser
Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential (NASDAQ:CSTL) - Seeking Alpha
Does Castle Biosciences Inc. have strong EBITDA margins2025 Major Catalysts & Weekly High Return Stock Opportunities - خودرو بانک
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):